Item 8.01 Other Events. On February 23, 2026, MacroGenics, Inc. issued a press release announcing that the U. S. Food and Drug Administration (the “FDA”) has placed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab, an investigational, bispecific DART® molecule that targets PD-1 and CTLA-4, in patients with gynecologic cancers.

Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit Number Description of Exhibit 99.1 Press Release dated February 23, 202 6 ────────────────────────────────────────────────────────────────────────────────────────────── 104 Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 23, 2026 MACROGENICS, INC. ───────────────────────────────────────────────────────────────────────────────────────────────── By: /s/ Jeffrey Peters